Study Gives Insights Into How Alzheimer’s Disease Kills Brain Cells

Exactly how Alzheimer’s disease kills brain cells is still somewhat of a mystery, but University of Michigan researchers have uncovered a clue that supports the idea that small proteins prick holes into neurons.

The team also found that a certain size range of clumps of these proteins are particularly toxic to cells, while smaller and larger aggregates of the protein appear to be benign.

The findings, which appear in the journal PLOS ONE, add important detail to the knowledge base regarding this disease that affects 5.4 million Americans in 2012 but remains incurable and largely untreatable. The results could potentially help pharmaceutical researchers target drugs to the right disease mechanisms.

Amyloid plaques on axons of neurons affected by Alzheimer’s disease. (stock image)

The U-M findings strongly support the idea that amyloid peptides damage the membrane around nerve cells and lead to uncontrolled movement of calcium ions into them. Calcium signaling is an important way that cells communicate and healthy cells regulate its flow precisely. The toxic mechanism implicated in the new study could act on its own or together with the other proposed courses and ultimately lead to a loss of brain cells in patients, the researchers say.
“There’s a good chance Alzheimer’s is caused, at least in part, by four- to 13-peptide aggregates that punch holes in cells and kill them gradually after prolonged exposure,” said Michael Mayer, an associate professor of biomedical engineering and chemical engineering who led the research.

“The size range of amyloid clumps that we identified as the most pore-forming was also the most toxic. The correlation is staggering. In the conditions of the culture dish, these results strongly suggest that pore formation by amyloid-beta is responsible for neuronal cell death.”

Using observation and sophisticated statistical analysis, the team explored whether the peptides’ tendency to poke holes in cell membranes correlated with the death of actual cells under the same conditions.

To conduct the experiment, Panchika Prangkio, a Ph.D. student in Mayer’s lab, formed amyloid-beta aggregates in water over 0, 1, 2, 3, 10 and 20 days. She measured how well amyloid clumps of various sizes punched pores in a lipid bilayer that mimicked a cell membrane. And, separately, but with the same amyloid samples, the team observed how many cells died and determined which size amyloids were in the sample at each time point. The researchers used cells from a human nerve cell cancer line.

Their finding that mid-size amyloid clumps are most toxic supports recent theories that individual peptides as well as longer amyloid fibers might be protective, rather than harmful, the researchers say. The smallest and largest aggregates were negatively correlated with cell death, which suggests they may bind with the dangerous mid-length clumps and trap them in a nontoxic form.

The work could help advance the search for Alzheimer’s treatments that would work by blocking pore formation by mid-sized amyloid-beta clumps. And they could raise questions about the potential efficacy of drugs (such as Bapineuzumab) that aim to remove large aggregates of amyloid beta.

“The better the research community understands how Alzheimer’s operates, the more likely we are to develop effective treatment,” Mayer said.

Citation